Form 4: IGM Biosciences CEO Mary Beth Harler Acquires Shares and Stock Options

IGM Biosciences CEO Mary Beth Harler reports acquisition of common stock and stock options.

Summary

• On October 2, 2024, Mary Beth Harler, CEO of IGM Biosciences, acquired 185,000 shares of common stock and 370,000 stock options.
• The common stock was acquired at a price of $0.
• The stock options have an exercise price of $14.4 and expire on October 2, 2034.
• Following the transaction, Harler directly owns 348,740 shares of common stock and 370,000 stock options.
• The restricted stock units (RSUs) vest over time, with one-third vesting on November 12, 2026, and the remainder vesting in equal installments every three months thereafter, contingent upon continued service.
• The stock options vest monthly, with 1/48th of the shares vesting on October 30, 2024, and each month thereafter, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO acquiring shares and options suggests confidence, but it's a routine transaction.

Positives

• The CEO's acquisition of shares and stock options could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the Reporting Person remaining a service provider through each vesting date.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates